Journal articles: 'Vergote'

1

SWIGGERS, P. "J. Vergote." Orbis 35 (January 1, 1992): 354–57. http://dx.doi.org/10.2143/orb.35.0.2012845.

APA, Harvard, Vancouver, ISO, and other styles

2

QUAEGEBEUR, J. "Bibliographie 1975-1987 J. Vergote." Orientalia Lovaniensia Periodica 23, no. 1 (June 2, 2005): 9–13. http://dx.doi.org/10.2143/olp.23.1.519163.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Głaz, Stanisław. "Religious Experience according to Antoine Vergote." Forum Philosophicum 1 (1996): 144–45. http://dx.doi.org/10.5840/forphil1996118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Winter-Roach, B., and H. C. Kitchener. "Response to the Letter of Vergote." International Journal of Gynecological Cancer 14, no. 2 (March 2004): 397. http://dx.doi.org/10.1111/j.1048-891x.2004.014235.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Winter-Roach, B., and H. C. Kitchener. "Response to the Letter of Vergote." International Journal of Gynecologic Cancer 14, no. 2 (2004): 397. http://dx.doi.org/10.1136/ijgc-00009577-200403000-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

QUAEGEBEUR, J. "In Memoriam Prof. Dr. J. Vergote (1910-1992)." Orientalia Lovaniensia Periodica 23, no. 1 (June 2, 2005): 5–7. http://dx.doi.org/10.2143/olp.23.1.519162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Green, John A. "Response to Vergote letter on early ovarian cancer." Gynecologic Oncology 94, no. 2 (August 2004): 607–8. http://dx.doi.org/10.1016/j.ygyno.2004.02.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Aletti, Mario. "A figura da ilusão na literatura psicanalítica da religião." Psicologia USP 15, no. 3 (2004): 163–90. http://dx.doi.org/10.1590/s0103-65642004000200009.

Full text

Abstract:

Este trabalho acompanha a história e evolução do modelo da ilusão aplicado à vivência religiosa, a partir das concepções de Freud, Pfister, teóricos das relações objetais, Winnicott, Vergote e Rizzuto, delineando as perspectivas abertas por essas contribuições teóricas, bem como seus limites.

APA, Harvard, Vancouver, ISO, and other styles

9

Tomcsányi, Teodóra. "Antoine Vergote, a vallás pszichológiájának és empirikus, pszichoanalitikus megközelítésének iskolateremtő alakja." Magyar Pszichológiai Szemle 63, no. 4 (December 1, 2008): 733–46. http://dx.doi.org/10.1556/mpszle.63.2008.4.7.

Full text

Abstract:

A tanulmány Antoine Vergote több évtizedes, a vallás pszichológiájának európai fejlődésére nagy hatást gyakorló munkássága mentén ad betekintést ezen tudományterületbe, amely a hosszú elzártság következtében a magyar tudományos köztudatban csekély helyet kaphatott.Vergote széles elméleti háttérre támaszkodó életművén és pszichoanalitikus irányultságú iskolaalapító munkásságán keresztül ismertet meg a valláspszichológia úttörőjének sokszínű, empirikus kutatásokon alapuló tudományos módszereivel, előzetes megfontolásaival és több diszciplína megközelítését is inte_i

APA, Harvard, Vancouver, ISO, and other styles

10

McDargh, John. "Rebuilding Fences and Opening Gates: Vergote on the Psychology of Religion." International Journal for the Psychology of Religion 3, no. 2 (April 1993): 87–93. http://dx.doi.org/10.1207/s15327582ijpr0302_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Rocha, Gabriel Kafure da. "A ÉTICA DA LIBERDADE EM KIERKEGAARD: ENTRE ANALÍTICOS E CONTINENTAIS." Sapere Aude 6, no. 12 (January 3, 2016): 630. http://dx.doi.org/10.5752/p.2177-6342.2015v6n12p630.

Full text

Abstract:

RESUMOA investigação da liberdade como tornar-se a si mesmo em Kierkegaard tem sido amplamente debatida por filósofos e comentadores europeus. Nesse contexto, é possível dizer que algumas tendências analíticas da meta-ética como as de Rudd e Davenport se contrapõem as interpretações francesas de Vergote e Ricouer. Nesse sentido, pretende-se fazer uma análise da questão clássica da subjetividade em Kierkegaard: escolher a si mesmo para tornar-se um indivíduo autêntico e livre. PALAVRAS-CHAVE: Kierkegaard. Tornar-se. Escolha. Liberdade.

APA, Harvard, Vancouver, ISO, and other styles

12

Tomcsányi, Teodóra. "Antoine Vergote, Founder of the Empirical and Psychoanalytical Approach in the Psychology of Religion." European Journal of Mental Health 5, no. 1 (June 1, 2010): 45–58. http://dx.doi.org/10.1556/ejmh.5.2010.1.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Byrnes, Joseph. "Guilt and Desire: Religious Attitudes and Their Pathological Derivatives. Antoine Vergote , M. H. Wood." Journal of Religion 69, no. 4 (October 1989): 588–89. http://dx.doi.org/10.1086/488237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Díez Barroso, Santiago. "Para una hermenéutica vital de la Palabra: Viva lectio est vita bonorum." Estudio Agustiniano 52, no. 1-3 (September 2, 2021): 429–88. http://dx.doi.org/10.53111/estagus.v52i1-3.111.

Full text

Abstract:

He elegido las coordenadas, que ofrece lo que he llamado “una hermenéutica vital”, como las más adecuadas, para glosar el recuerdo del compañero-profesor D. Senén Vidal García (1941-2016). En efecto, como pocos, interpretó vital y teóricamente, siempre con maestría cercana y honda, el mensaje neotestamentario. Al alimón he querido honrar la memoria de otros entrañables maestros míos, buenos a carta cabal, que se situaron en una longitud de onda similar y que, también, vivieron lo que enseñaron, dejando en mí tan honda huella: M. Legido, J. Velicia, P. Ricoeur, J. Ladrière, A. Gesché, A. Vergote.

APA, Harvard, Vancouver, ISO, and other styles

15

Rocha, Gabriel Kafure da, and Estela Araújo Silva. "As ironias do conceito socrático em Kierkegaard." Trilhas Filosóficas 11, no. 1 (June 26, 2018): 239–57. http://dx.doi.org/10.25244/tf.v11i1.3042.

Full text

Abstract:

Resumo: O presente artigo visa fazer uma análise do socratismo em O conceito de Ironia de Kierkegaard, para isso, pressupomos o valor da ironia na antiguidade e das visões pós-socráticas. Buscamos assim, também, entender essencialmente a relação entre o filósofo e as ironias dos pontos de vista pagão e cristão. Por fim, vimos na visão da morte uma ironia do destino, que por sua vez abre a perspectiva entre o trágico e o cômico. Para tal investigação, utilizamos comentadores como Vergote, Farago, Politis, Stewart e principalmente Reichmann. Dessa maneira, chegaremos ao desfecho no qual Kierkegaard faz a transposição da realidade grega para a atualidade do seu contexto, com a possibilidade do uso adequado de uma ironia controlada.Palavras-chave: Humor. Cômico. Destino. Abstract: This article aims to make an analysis of Socratism in Kierkegaard's Concept of Irony, for which we presuppose the value of irony in antiquity and post-Socratic visions. We also seek to understand, essentially, the relation between the philosopher and the ironies from the pagan and Christian point of views. Finally, we saw in the vision of death an irony of fate, which in turn opens the perspective between the tragic and the comic. For such investigation, we use commentators like Vergote, Farago, Politis Stewart and mainly Reichmann. In this way, we will arrive at the outcome in which Kierkegaard transposes Greek reality to the actuality of his context, with the possibility of proper use of controlled irony.Keywords: Humor. Comic. Destiny. REFERÊNCIASAMARAL, Ilana. O 'Conceito' de Paradoxo (Contantemente referido a Hegel) - Fé, história e linguagem em S. Kierkegaard. Tese de Doutorado. São Paulo: PUC, 2008. 247 f.FARAGO, France. Compreender Kierkegaard. Tradução de Ephraim Alves. Petrópolis: Ed. Vozes, 2006.GOUVÊA, Ricardo. Paixão pelo paradoxo: Uma introdução a Kierkegaard. São Paulo: Fonte Editorial, 2006.HOWLAND, Jacob. Kierkegaard and Socrates: A study in philosophy and faith. Cambridge: Cambridge University Press, 2006.KIERKEGAARD, Søren. O conceito de Ironia constantemente referido à Sócrates. Tradução de Álvaro Valls. Petrópolis: Editora Vozes, 1991._______. Ponto de vista explicativo da minha obra de escritor: uma comunicação direta, relatório à História. Tradução de João Gama. Lisboa: Edições 70, 2002.OUBINHA, Oscar. Loquere ut Videam: “’Guilty?/‘Not Guilty?” and The writing of irony. IN: JUSTO; SOUSA: ROSFORT. Kierkegaard and the challenges of infinitude – Philosophy and literature in Dialogue. Lisboa: CFUL, 2013.REICHMANN, Ernani. Soeren Kierkegaard: Textos selecionados. Curitiba: Editora Imprensa Universitária, 1978._______. Intermezzo lírico-filosófico: Carta a Carlos Galvez. Curitiba: Edição do autor, 1963.SILVA, Fernando. A subjectivity raised to the second power – Kierkegaard’s view of Schelegel’s Concept of Irony. In: JUSTO; SOUSA: ROSFORT. Kierkegaard and the challenges of infinitude: Philosophy and literature in Dialogue. Lisboa: CFUL, 2013.STEWART, Jon. Søren Kierkegaard: subjetividade, ironia e a crise da modernidade. Tradução de Humberto Souza. Petrópolis: Vozes, 2017.PLATÃO. Apologia de Sócrates. In: Os pensadores. Tradução de Jaime Bruna. 2ª Ed.. São Paulo: Abril Cultural, 1980._______. Diálogos: Eutífron – Apologia de Sócrates – Críton – Fédon. Tradução de Marcio Pugliesi. São Paulo: Hemus, 1977.POLITIS, Hélène. Le concept de philosophie constamment rapporté à Kierkegaard. Paris: Editions Kimé, 2009.VERGOTE, Henri. Sens et Repetition: essai sur la ironie kierkegaardiene. Paris: Cerf/Orante, 1982.

APA, Harvard, Vancouver, ISO, and other styles

16

Cherbuis, Grégory. "Analyser et améliorer la traçabilité dans les industries agroalimentaires - catherine lecomte, chi-dung ta et marie-hélène vergote." Revue Française de Gestion Industrielle 25, no. 2 (June 1, 2006): 85–87. http://dx.doi.org/10.53102/2006.25.02.555.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Dreyer, Y. "Vergewe en vergeet: ‘n Pastorale perspektief." Verbum et Ecclesia 26, no. 1 (October 2, 2005): 16–34. http://dx.doi.org/10.4102/ve.v26i1.211.

Full text

Abstract:

This article focuses on pastoral care concerning people who have been victimised by others. The aim is to highlight the theological dilemma created for such people by the Christian imperative to forgive. The article argues that pastoral care goes beyond this imperative. The focus is rather on healing and wholeness. After this has been achieved, true compassion toward others who are down-trodden and have been hurt, becomes possible. In this way forgiveness can be internalised. This pastoral approach is theoretically substantiated by the philosophy of Paul Ricoeur and the practical theology of Donald Capps.

APA, Harvard, Vancouver, ISO, and other styles

18

Gallego, Miriam. "Claves de la experiencia religiosa en Aparecida: Un aporte para la pastoral juvenil." Alteridad 5, no. 2 (December 30, 2010): 39–46. http://dx.doi.org/10.17163/alt.v5n2.2010.06.

Full text

Abstract:

Para reflexionar sobre el tema de experiencia religiosa en el Documento de Aparecida es importante responder inicialmente a la pregunta: ¿qué entendemos por experiencia religiosa?La palabra ‘experiencia’ deriva del verbo latino ‘perior’ y hace referencia a probar, tantear, atravesar, conocer algo. De este concepto se derivan las múltiples significaciones dadas a la palabra experiencia.La palabra religiosa deriva del término religión e indica la palabra latina religare o re-legere y hace referencia a juntar, reunir, volver atar. En sentido amplio sería el conjunto de acciones encaminadas a ‘volver a atar’ a la humanidad después de haberse soltado de la Naturaleza.Según A. Vergote, la experiencia religiosa, en primer lugar, es identificada como ‘experiencia de lo sagrado’, comprendido como conocimiento intuitivo estable y habitualmente accesible de una realidad sobrenatural presente al mundo y a las personas y que trasciende a ambos. En segundo lugar, como la ‘captación profundamente afectiva’ de una realidad sobrenatural que se revela como novedad que sorprende e interpela al hombre, transformándole duramente o pasajeramente, constituyendo un acontecimiento que sobreviene al hombre y da nuevo sentido a su vida.

APA, Harvard, Vancouver, ISO, and other styles

19

Stotts, Jonathan. "Obedience as Belonging: Catholic Guilt and Frequent Confession in America." Religions 10, no. 6 (June 5, 2019): 370. http://dx.doi.org/10.3390/rel10060370.

Full text

Abstract:

From the late 19th to the mid-20th century, the practice of private confession to a priest was a mainstay of Catholic parish life in the United States. By the 1970s, Catholics had largely abandoned the practice of private confession. One dominant narrative among Catholic theologians and clergy, identified chiefly with the papacy of John Paul II, attributes the decline in confession to the loss of healthy guilt that took place during the cultural upheaval of the 1960s. In conversation with the work of psychologist and philosopher Antoine Vergote, the present article challenges this narrative, arguing that a collective and unhealthy Catholic guilt existed among American Catholics well before the 1960s and in fact characterized the period in which private confession was practiced most frequently. I contend that obedience to moral prescriptions was not, for ordinary Catholics, part of an ethical program of self-reform but the condition for belonging to a church body that emphasized obedience. Finally, examining the relationship between weekly reception of communion and confession, I suggest that private confession emerged to support frequent communion, persisting only until the latter became standard practice among Catholics in the United States.

APA, Harvard, Vancouver, ISO, and other styles

20

van den Heuvel, Esther, and Simon Groen. "Ouderen met onbegrepen klachten: vergeet het vergeten niet." Huisarts en Wetenschap 52, no. 13 (January 2009): 679–81. http://dx.doi.org/10.1007/bf03085839.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Cuny-Salazar, José Antonio. "Vergote, Antoine (1998) Culpa y deseo: dos ejes cristianos y la desviación patológica Lima: Universidad de Lima/ Fondo de Cultura Económica. 295 pp." Persona, no. 002 (November 3, 1999): 268. http://dx.doi.org/10.26439/persona1999.n002.1712.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Lackamp, O. J. M., and H. G. L. M. Grundmeijer. "Vergrote lymfeklieren." Huisarts en wetenschap 44, no. 11 (November 2001): 204–9. http://dx.doi.org/10.1007/bf03082402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Lackamp, O. J. M. "Vergrote lymfeklier." Huisarts en wetenschap 54, no. 11 (November 2011): 627. http://dx.doi.org/10.1007/s12445-011-0305-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Liu, P., J. Moon, D. S. Alberts, B. J. Monk, M. Brady, and M. Markman. "A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 5080. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5080.

Full text

Abstract:

5080 Background: CA-125 progression criterion for OC by Vergote et al (JNCI 2000; 92:1534) has been widely adopted, with 35 U/ml as the most commonly used normal limit. Based on recent findings (ASCO Proceedings 2005, #5013), primary therapy cCR OC pts with nadir CA-125 ≤10 versus >10–20 versus >20–35 have different prognosis. We propose to modify the CA-125 progression criterion in this setting as follows: for pts with nadir ≤10, value ≥20 that is confirmed equals progression; for pts with nadir >10, value ≥ 2×nadir that is confirmed equals progression. This new criterion essentially treats 10 U/ml as the normal limit. Methods: The proposed criterion combined with RECIST was tested on SWOG 9701/GOG 178 pts (n = 287) and compared to the existing criterion. All pts achieved cCR from primary therapy and entered the above maintenance trial with CA125 ≤35. Results: Of 91 pts last known to be progression-free by existing criterion, 10 (11%) new progressions were called. Available CA-125 values continued to rise in all except 1 case (1%). For 196 pts with known progressive disease, the progression date was unchanged by the new criterion in 42%, and was earlier by ≤60 days in 31%, 61–180 days in 16% and >180 days in 11% (overall median days early = 56). Conclusions: In a series of 39 primary therapy cCR pts with CA-125 ≤35, Santillan et al found a progressive low-level increase in CA-125 to be strongly predictive of disease recurrence (JCO 2005; 23:9338). Similarly, initial testing of the proposed CA-125 criterion demonstrated a low false positive rate and early detection of disease progression >2 months in approximately 30% of the same first line complete responders with progressive disease during or after maintenance treatment. Such pts can potentially benefit from starting alternative treatments early. The proposed criterion should be further investigated. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

25

Vergote, Ignace, Erika Paige Hamilton, Ignacio Romero, Eva M. Guerra, Joseph Buscema, Annouschka Laenen, Tamar Perri, et al. "SIENDO/ENGOT-EN5: A randomized phase III trial of maintenance with selinexor/placebo after combination chemotherapy in patients with advanced or recurrent endometrial cancer." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): TPS6105. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps6105.

Full text

Abstract:

TPS6105 Background: Endometrial cancer is one of the most common gynecologic malignancies with increasing incidence and mortality. Patients with advanced disease that has relapsed or received prior platinum-based therapy or radiotherapy have limited options and the prognosis remains poor. Selinexor is a novel, oral selective inhibitor of nuclear export (SINE) which forces nuclear retention and activation of tumor suppressor proteins. Selinexor in combination with low dose dexamethasone was recently approved for patients with multiple myeloma. In addition, single agent selinexor has demonstrated broad activity in other hematologic malignancies and solid tumors. In a phase II study, 50 mg/m2 (~80 mg) selinexor administered twice weekly demonstrated a disease control rate of 35% with 2 confirmed partial responses among 23 patients with heavily pretreated endometrial cancer (Vergote I et al. Gynecol Oncol 2020). In the absence of approved maintenance therapies, we conducted this study to evaluate the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent endometrial cancer. Methods: This is a multicenter, double-blind, placebo-controlled, randomized phase III study in patients in partial or complete remission after completing at least 12 weeks of taxane-platinum combination therapy for primary Stage IV disease and recurrent disease (i.e., relapse after primary therapy for early stage disease including surgery and/or adjuvant therapy). A total of 192 patients will be enrolled at 80 sites in Europe, North America, and Israel. Patients will be randomized in a 2:1 ratio to either maintenance therapy with 80 mg oral selinexor once weekly or placebo. Stratification factors include primary Stage IV versus first recurrent disease at the time of taxane-platinum therapy and disease status after chemotherapy (partial versus complete response). Treatment will continue until disease progression. The primary endpoint is progression free survival (PFS) per RECIST v1.1. Secondary endpoints include disease-specific survival, overall survival, time to first subsequent therapy, time to second subsequent therapy, PFS on subsequent therapy and safety and tolerability. The study is currently open and enrolling patients. Clinical trial information: NCT03555422.

APA, Harvard, Vancouver, ISO, and other styles

26

Smith, Harriet. "Book Review Clinical Management of Ovarian Cancer Edited by Jonathan A. Ledermann, William J. Hoskins, Stanley B. Kaye, and Ignace B. Vergote. 298 pp., illustrated. London, Martin Dunitz, 2001. $125. 1-85317-704-0." New England Journal of Medicine 345, no. 2 (July 12, 2001): 152–53. http://dx.doi.org/10.1056/nejm200107123450220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

van Kimmenaede, Rob. "Eenzijdig vergrote tonsil." Huisarts en wetenschap 56, no. 2 (February 2013): 80–82. http://dx.doi.org/10.1007/s12445-013-0043-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Mendiola, Cesar, Ray Manneh, Tomas Pascual, Guillermo De Velasco, Estela Vega, Luis Manso, Ismael Ghanem, Eva M. Ciruelos, J, Seoane, and Hernan Cortes-Funes. "Neoadjuvant chemotherapy without a fixed number of cycles in advanced ovarian cancer not candidates for optimal primary surgery." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e15552-e15552. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15552.

Full text

Abstract:

e15552 Background: Neoadjuvant chemotherapy (N-CT) is a valid alternative for patients with advanced ovarian cancer (AOC) getting similar survival rates to primary debulking surgery (PDS) followed by chemotherapy (CT), with less postoperatory complications (Vergote et al N Engl J Med 2010;363:943-53). Our objective was to evaluate the results of N-CT with a flexible number of cycles according to the clinical and biological evolution of the patients. Methods: 22 patients with stage IIIC-IV AOC, diagnosed by laparoscope or cytology (no primary laparotomy) were registered between January 2007 and September 2011 and treated with N-CT including paclitaxel 175 mg/m2 and carboplatin AUC 6-5 every 3 weeks. The number of cycles of N-CT was dictated by the clinical response, CT scan and CA125 that could allow an interval debulking surgery (IDS) with intent of optimal cytoreduction (R0). After IDS consolidation chemotherapy treatment was given to complete a total of at least 8 cycles. Results: Median age 63.7 years (40 – 80). Histologic types: serous 28%, adenocarcinoma not specified 66%, endometrioid 4.5%. FIGO stage IIIC 57%, IV 43%, Median CA125 at diagnosis: 1744 U (157 – 14483). Mean N-CT cycles 7.8 (4-23). 90.1 % of patients responded before IDS, 2 patients progressed before surgery. Mean CA125 after N-CT was 20.5 U (9-108). 54% of patients achieved complete resection of all macroscopic disease during IDS (R0). 5/22 (22.7%) obtained a pathological complete response (pCR) (no microscopic tumour in all specimens removed). Complications in the postoperatory occurred in 2 patients consisting in suture dehiscence. The range of total number of CT cycles were as follows: <6: 4.54%; 7-8: 31.8%; 9-10: 31.8%, >10: 31.8%. With a mean follow-up of 22.4 months (4 - 57.6), 50% patients live without recurrence. Median PFS has not been reached. Conclusions: N-CT according to clinical and biologic response and not to a fixed number of cycles is an useful tool for patients with stage IIIC-IV AOC not candidates for optimal /R0 PDS, getting a high proportion of patients with optimal /R0 IDS. The complications of IDS are also very limited. pCR as surrogate marker for long-term survival in other tumours, has to be evaluated in AOC.

APA, Harvard, Vancouver, ISO, and other styles

29

Vergote, Ignace, Jose Alejandro Perez-Fidalgo, Erika P. Hamilton, Toon Van Gorp, Giorgio Valabrega, Annouschka Laenen, Amit M. Oza, et al. "SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): TPS5610. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps5610.

Full text

Abstract:

TPS5610 Background: Endometrial cancer (EC) is the most common gynecologic malignancy. Options for advanced or recurrent EC following platinum-based therapy and/or radiotherapy are limited and prognosis remains poor. Selinexor is a novel, oral selective inhibitor of nuclear export (SINE) which forces nuclear retention and activation of tumor suppressor proteins. Selinexor in combination with low dose dexamethasone is approved for relapsed/refractory multiple myeloma. In addition, selinexor monotherapy has demonstrated broad activity in other hematologic malignancies and solid tumors. In a phase 2 study, 50 mg/m2 (̃80 mg) selinexor administered twice weekly demonstrated a disease control rate ( SD ≥ 12 weeks or a PR) of 35% with 2 confirmed partial responses among 23 heavily pretreated EC patients); similar results were observed in 60 pts with platinum resistant or refractory ovarian cancer (median 5 prior regimens, ORR 8%, DCR 30%) (Vergote I et al. Gynecol Oncol 2020). In the absence of approved maintenance therapies, we conducted this study to evaluate the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent EC following platinum-based chemotherapy. Methods: This is a multicenter, double-blind, placebo-controlled, randomized phase 3 study in patients in partial (PR) or complete remission (CR) after completing at least 12 weeks of taxane-platinum combination therapy for primary Stage IV disease and recurrent disease (i.e., relapse after primary therapy for early stage disease including surgery and/or adjuvant therapy). A total of 248 patients will be enrolled at 80 sites in Europe, North America, and Israel. Patients will be randomized in a 2:1 ratio to either maintenance therapy with 80 mg oral selinexor once weekly or placebo. Stratification factors include primary Stage IV versus first recurrence at the time of taxane-platinum therapy and disease status after chemotherapy (PR vs CR). Treatment will continue until disease progression. The primary endpoint is progression free survival (PFS) per RECIST v1.1. Secondary endpoints include disease-specific survival, overall survival, time to first subsequent therapy, time to second subsequent therapy, PFS on subsequent therapy and safety and tolerability. The study is currently open and enrolling patients. Clinical trial information: NCT03555422.

APA, Harvard, Vancouver, ISO, and other styles

30

Lindeboom, J., and R. Smit. "Vergeten en vergeten is twee." Neuropraxis 7, no. 1 (February 2003): 19–23. http://dx.doi.org/10.1007/bf03071040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Zamagni, C., P. De Iaco, M. Rosati, N. Cacciari, F. Rosati, D. Rubino, and A. A. Martoni. "Effect of six courses of neoadjuvant chemotherapy on pathological complete remission in advanced ovarian cancer." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 5513. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5513.

Full text

Abstract:

5513 Background: The role and the duration of NACT in ovarian cancer are debated. A randomized trial comparing upfront surgery versus 3 courses of NACT (Vergote 2008) demonstrated similar survival, but less morbidity in favor of NACT. However, pathological complete remissions (pCR) were rare and 68% of pts still had lesions greater than 2 cm after 3 courses of NACT. The rate of pCR correlates with a better survival in other tumors, such as breast cancer, and its rate is higher after 6–8 courses of NACT. We conducted this study to verify the incidence of optimal pathological remission after 6 courses of NACT. Methods: Eligible pts had stage IIIC-IV EOC unsuitable for optimal upfront surgery and were treated with 6 cycles of carboplatin AUC 5 and paclitaxel 175 mg/sm, every 3 weeks before surgery. We considered as optimal pathological responders: 1) the pts with absence of cancer cells in surgical specimens, and 2) the pts with no macroscopic residual after surgery and with only small clusters or individual cancer cells in surgical specimens. All the other cases were considered as pathological nonresponders, even if a relevant shrinkage of tumor burden and an optimal surgical debulking were obtained. Results: 35 stage IIIC/IV pts were enrolled; 33 (94%) completed 6 courses of NACT. We observed 18 (51%) pathological responders, and 17 pathological nonresponders (as defined above). Overall, in 20 (57%) pts the goal of no residual tumor after surgery was achieved. After a median follow-up of 21 mo.s, 21 pts progressed (median PFS 15 mo.s) and 10 pts died. As expected, pts with tumor residual after surgery less than 1 cm survived significantly longer than patients with a greater residual (p .0005). The median overall survival was longer in pathological responders (median not reached) vs nonresponders (19.8 mo.s) (p.03). Conclusions: In our study an optimal pathological response occurred in 51% of cases after 6 cycles of carboplatin-paclitaxel, doubling the results described in the literature with 3 courses of NACT. Given that an optimal pathological response correlates with a longer survival compared to a sub-optimal one, a randomized study of 6 vs 3 courses of NACT in order to verify if the increase in pathological response rate will translate into a survival benefit is warranted. No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

32

van den Bold, Ingeborg. "Vergeten." TBV – Tijdschrift voor Bedrijfs- en Verzekeringsgeneeskunde 14, no. 5 (May 2006): 279. http://dx.doi.org/10.1007/bf03074395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Lambooy, Jan. "Vergeten grondlegger." AGORA Magazine 28, no. 4 (September 1, 2012): 47. http://dx.doi.org/10.21825/agora.v28i4.2399.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Visser, Martijn. "Vergeten verloskunde." Algemeen Nederlands Tijdschrift voor Wijsbegeerte 112, no. 4 (October 1, 2020): 390–93. http://dx.doi.org/10.5117/antw2020.4.004.viss.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kreyns, J. M. "Tandtechniekkosten vergeten." TandartsPraktijk 30, no. 8 (August 2009): 9–11. http://dx.doi.org/10.1007/bf03080946.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Heynick, Frank. "Meesterwerk Vergeten." Tandartspraktijk 36, no. 6 (August 2015): 54–55. http://dx.doi.org/10.1007/s12496-015-0090-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

van Genugten, Will. "Vergeten kind." Maatwerk 11, no. 3 (June 2010): 30–31. http://dx.doi.org/10.1007/s12459-010-0062-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Beckers, Joep. "Niemand vergeten." Fizier 35, no. 1 (February 2018): 30–31. http://dx.doi.org/10.1007/s40739-018-0010-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Draper, Susana. "Herinneren en vergeten." Témoigner. Entre histoire et mémoire, no. 118 (October 1, 2014): 113–19. http://dx.doi.org/10.4000/temoigner.1103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Henskens, Renée, Bernd Wondergem, Jolanda Mooij, Christel van Zon, and Lisette Schoutens. "‘Vergeet Mij Niet’." PROCES 97, no. 2 (May 2018): 86–97. http://dx.doi.org/10.5553/proces/016500762018097002003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Beheydt, Ludovic. "De Vergeten Leerprincipes." Lexicon en taalverwerving 34 (January 1, 1989): 42–50. http://dx.doi.org/10.1075/ttwia.34.06beh.

Full text

Abstract:

Recently learning psychologists have tried to prove that learning vocabulary in paired lists is more efficient than learning vocabulary in contexts. However, closer inspection of their experimental designs reveals undeniably that the evidence presented is not very reliable. The experiments are based on linguistically naive assumptions. Polysemy within and heterosemy between languages have not sufficiently been taken into account. The assumptions concerning the mental lexicon are equally naive in that they do not account for the highly structured design of the mental lexicon. Fundamental insights from linguistics and learning psychology support contextual learning of vocabulary. Especially vocabulary learning by means of "pregnant" contexts that foster mental elaboration seems to be highly recommendable. It is furthermore argued that the acquisition of the polysemous and syntactically and morphologically versatile profile of vocabulary items should begin with the prototypical meaning of words, which can be inferred from word association lists obtained with native speakers

APA, Harvard, Vancouver, ISO, and other styles

42

Fleskens, A. J. H. M., M. R. M. Scheltinga, P. V. van Eerten, L. H. M. Verhoef, H. L. M. Pasmans, and G. Vreugdenhil. "De ‘vergeten’ ziekte." Critical care 6, no. 2 (April 2009): 6–11. http://dx.doi.org/10.1007/bf03088383.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Rudolf, Bernhard. "Bestandsgeschäft besser vergüten." Versicherungsmagazin 65, no. 6 (May 28, 2018): 3. http://dx.doi.org/10.1007/s35128-018-0089-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Hoogeveen, Frans. "Spreken over vergeten." Denkbeeld 31, no. 5 (October 2019): 4. http://dx.doi.org/10.1007/s12428-019-0071-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Rudolf, Bernhard. "Beratung angemessen vergüten." AnlagePraxis 2, no. 10 (September 2016): 5. http://dx.doi.org/10.1007/s40975-016-0033-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Verkade, Paul-Jeroen, and Carola Döpp. "Spreken over vergeten." Denkbeeld 31, no. 5 (October 2019): 30–32. http://dx.doi.org/10.1007/s12428-019-0060-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Reisner, Hubert. "Nachhaltigkeit und Vergabe." Recht und Praxis der öffentlichen Auftragsvergabe 21, no. 1 (2021): 1. http://dx.doi.org/10.33196/rpa202101000101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

van Bruggen, Folkert, and Henk Bosveld. "COPD: vergrote kans op exacerbatie bij bètablokker?" Huisarts en wetenschap 58, no. 10 (October 2015): 558. http://dx.doi.org/10.1007/s12445-015-0293-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Tibayrenc, M. "Laurence Vergne." Infection, Genetics and Evolution 7, no. 5 (September 2007): 674. http://dx.doi.org/10.1016/j.meegid.2007.05.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Miller, Marvin E. "Cavum Vergae." Archives of Neurology 43, no. 8 (August 1, 1986): 821. http://dx.doi.org/10.1001/archneur.1986.00520080061022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Vergote'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles